ERIS Lifesciences Ltd

ERIS Lifescience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

ERIS Lifesciences Ltd

₹ 1,376 -1.55%
01 Jun 4:01 p.m.
eris.co.in BSE: 540596 NSE: ERIS
About

ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]

Key Points

Market Position
The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market. [1]

Website BSE NSE
  • Market Cap ₹ 19,085 Cr.
  • Current Price ₹ 1,376
  • High / Low ₹ 1,910 / 1,200
  • Stock P/E 30.2
  • Book Value ₹ 282
  • Dividend Yield 0.53 %
  • ROCE 14.1 %
  • ROE 18.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 4.88 times its book value
  • Promoter holding has decreased over last quarter: -0.93%
  • Tax rate seems low

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE 250 SmallCap Index BSE 400 MidSmallCap Index

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
403 467 505 486 551 720 741 727 705 773 792 807 757
284 297 324 311 402 470 477 477 453 496 504 526 484
Operating Profit 119 170 181 176 148 250 265 250 252 277 288 282 272
OPM % 30% 36% 36% 36% 27% 35% 36% 34% 36% 36% 36% 35% 36%
1 1 3 4 15 2 5 4 8 4 3 -17 2
Interest 9 17 16 18 33 60 59 57 54 49 50 49 46
Depreciation 35 41 42 46 54 76 80 81 77 71 69 70 70
Profit before tax 76 112 126 116 77 116 129 116 129 161 173 145 159
Tax % 19% 17% 3% 12% -4% 22% 25% 25% 21% 22% 22% 25% -75%
61 94 122 101 80 90 96 87 102 125 134 109 279
EPS in Rs 4.81 6.98 9.07 7.55 5.22 6.12 6.73 6.15 6.89 8.66 8.82 7.32 20.33
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
546 597 750 856 982 1,074 1,212 1,347 1,685 2,009 2,894 3,129
427 425 480 533 637 702 781 858 1,146 1,332 1,876 2,009
Operating Profit 118 172 269 322 345 372 431 489 539 677 1,018 1,120
OPM % 22% 29% 36% 38% 35% 35% 36% 36% 32% 34% 35% 36%
7 3 25 26 31 12 9 22 9 22 18 -9
Interest 0 0 1 11 23 2 2 4 26 85 231 193
Depreciation 16 20 23 26 36 50 43 65 117 183 315 280
Profit before tax 109 154 270 312 317 331 394 442 405 431 489 639
Tax % 18% 13% 9% 6% 8% 11% 10% 8% 8% 8% 23% -1%
89 135 247 295 291 297 355 406 374 397 375 648
EPS in Rs 6,489.45 9,714.18 17.95 21.39 21.15 21.84 26.16 29.88 28.10 28.82 25.84 44.72
Dividend Payout % 0% 63% 0% 0% 0% 13% 21% 20% 26% 0% 28% 16%
Compounded Sales Growth
10 Years: 18%
5 Years: 21%
3 Years: 23%
TTM: 8%
Compounded Profit Growth
10 Years: 17%
5 Years: 12%
3 Years: 19%
TTM: 80%
Stock Price CAGR
10 Years: %
5 Years: 15%
3 Years: 29%
1 Year: -13%
Return on Equity
10 Years: 21%
5 Years: 18%
3 Years: 16%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.14 0.14 14 14 14 14 14 14 14 14 14 14
Reserves 266 299 553 848 1,137 1,283 1,563 1,895 2,182 2,573 2,841 3,889
1 0 1 377 176 0 7 84 877 2,781 2,478 2,359
91 98 124 170 175 205 202 233 337 1,366 1,412 1,104
Total Liabilities 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 6,734 6,744 7,366
72 71 232 771 761 875 854 918 2,568 4,319 5,306 5,188
CWIP 0 0 0 0 3 4 2 27 22 20 67 171
Investments 167 190 303 365 356 78 294 520 37 16 67 62
119 136 157 271 383 544 636 761 783 2,379 1,304 1,945
Total Assets 357 397 692 1,408 1,502 1,502 1,785 2,226 3,410 6,734 6,744 7,366

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
90 131 200 235 223 271 375 378 292 486 1,065 538
-92 -44 -184 -590 -5 123 -323 -320 -975 -1,828 -78 -369
0 -84 -24 363 -221 -335 -82 -45 688 1,380 -881 -314
Net Cash Flow -2 4 -8 8 -3 60 -30 14 5 38 105 -145
Free Cash Flow 77 108 150 210 186 125 350 258 -550 357 910 241
CFO/OP 96% 97% 94% 94% 85% 87% 103% 94% 68% 87% 114% 59%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 16 16 24 28 31 53 42 44 63 77 58 79
Inventory Days 223 178 195 178 196 148 145 166 136 182 171 200
Days Payable 142 92 134 247 200 213 157 166 129 210 170 151
Cash Conversion Cycle 97 102 84 -40 28 -12 30 44 70 48 59 129
Working Capital Days 15 9 23 -13 -17 59 64 75 50 -296 -49 -71
ROCE % 47% 53% 60% 34% 26% 25% 27% 25% 17% 11% 12% 14%

Insights

In beta
Mar 2013 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Guwahati Facility Tablet Utilization
% ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Chronic Segment Contribution to Revenue
%
Field Force Strength (Medical Representatives)
Number
Indian Pharmaceutical Market (IPM) Rank
Rank
Number of Doctors reached
Number
Insulin Market Share
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
52.86% 54.91% 54.90% 54.90% 54.88% 54.87% 54.86% 54.85% 54.83% 54.85% 54.85% 53.92%
13.78% 13.20% 13.13% 14.27% 14.59% 8.01% 8.36% 8.43% 8.39% 7.21% 6.85% 6.39%
10.73% 14.52% 14.55% 15.63% 16.23% 18.64% 18.07% 18.07% 18.18% 19.36% 20.31% 20.35%
22.63% 17.37% 17.41% 15.20% 14.30% 18.47% 18.73% 18.64% 18.59% 18.57% 17.97% 19.33%
No. of Shareholders 44,16942,24546,49651,75344,17646,34653,31450,08752,22559,43854,71351,656

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls